early-lineage stem cells used in research-stage protocols.
Fetal stem cells carry broad differentiation potential and low immunogenicity. They form the historical core of several European regenerative programmes and remain a defined research area.
The therapeutic value of Fetal Stem Cells lies less in cells "becoming" new tissue and more in their paracrine signalling — the growth factors and vesicles they release to calm inflammation and recruit the body's own repair. Delivery is matched to the target: intravenous for systemic conditions, or localised where appropriate.
Educational information. Fetal Stem Cells protocols for several conditions remain investigational; outcomes vary by patient.
GMP-certified regenerative medicine in the heart of the EU — from €3,000–8,000, a fraction of US or German pricing. Personalised protocols for international patients from 50+ countries.
Free medical review